Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

BACKGROUND AND PURPOSE: The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevacizumab (T...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Radiat Oncol
Main Authors: Ohno, Makoto, Miyakita, Yasuji, Takahashi, Masamichi, Igaki, Hiroshi, Matsushita, Yuko, Ichimura, Koichi, Narita, Yoshitaka
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852964/
https://ncbi.nlm.nih.gov/pubmed/31718669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13014-019-1389-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki